Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Aldesleukin + Anti-hCD70 CAR-T cells |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Aldesleukin | Proleukin | IL-2|Interleukin-2|IL2 | Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary). | |
Anti-hCD70 CAR-T cells | Anti-hCD70 CAR T cells|Anti-hCD70 CAR autologous PBLs | Anti-hCD70 CAR-T cells are patient-derived peripheral blood lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD70 and containing the extracellular region of CD27 fused to TNFRSF9 (4-1BB) and CD3-zeta, which potentially inhibit the growth of CD70-expressing tumors (PMID: 27803044). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02830724 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + Anti-hCD70 CAR-T cells | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | Recruiting | USA | 0 |